Vertex Pharmaceuticals Gross Profit

The latest gross profit for VRTX is $11B as of June 2026. That compares with $9.8B in the prior-year period — up 10.1% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Vertex Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, VRTX's gross profit moved from $9.8B to $11B — a 10.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vertex Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, VRTX currently prints $11B for gross profit, while the sector average sits near $67B. That is roughly 83.8% below the sector mean. Large gaps often invite a closer look at Vertex Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $11B for VRTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting VRTX's gross profit ($11B), review year-over-year change from $9.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.